CPM-LAD

CPM-LAD
Clinical data
Other namesCPMLAD; CYPM-LAD; CYPMLAD; 6-(Cyclopropylmethyl)-6-nor-LSD; N(6)-Cyclopropylmethyl-norLSD;
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • (6aR,9R)-7-(cyclopropylmethyl)-N,N-diethyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
Chemical and physical data
FormulaC23H29N3O
Molar mass363.505 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)CC5CC5
  • InChI=1S/C23H29N3O/c1-3-25(4-2)23(27)17-10-19-18-6-5-7-20-22(18)16(12-24-20)11-21(19)26(14-17)13-15-8-9-15/h5-7,10,12,15,17,21,24H,3-4,8-9,11,13-14H2,1-2H3/t17-,21-/m1/s1
  • Key:XTKDRKBVDJFYNW-DYESRHJHSA-N

CPM-LAD, or CYPM-LAD, also known as 6-(cyclopropylmethyl)-6-nor-LSD, is a serotonin receptor modulator and putative psychedelic drug of the lysergamide family. It is the analogue of LSD in which the methyl group at the 6 position has been replaced with a cyclopropylmethyl group.

Use and effects

Unlike related lysergamides, CPM-LAD was not mentioned in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved) and is not known to have been tested in humans.

Interactions

Pharmacology

Pharmacodynamics

CPM-LAD showed affinity (Ki) values for serotonin receptors of 10.9 nM for serotonin-labeled 5-HT1 receptors and 7.7 nM for ketanserin-labeled 5-HT2 receptors. These affinities were very similar to but slightly lower than those of LSD. CPM-LAD fully substituted for LSD in rodent drug discrimination tests with an ED50Tooltip median effective dose of 0.067 μmol/kg, relative to a dose of 0.046 μmol/kg in the case of LSD (with CPM-LAD about 1.5-fold less potent than LSD). Additional pharmacology for CPM-LAD has also been published.

History

CPM-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University in 1987. Subsequently, it was patented by Gilgamesh Pharmaceuticals in 2022, who further studied and described its pharmacology. Derivatives of CPM-LAD have also been patented by Daniel Trachsel and Matthias Liechti and colleagues in association with MindMed.

Society and culture

Canada

CPM-LAD is not a controlled substance in Canada as of 2025.

See also